AlbA-DCA

AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A (AlbA) to a dichloroacetate acid (DCA) subunit. AlbA-DCA can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in tumor microenvironment (TME), and also selectively kills cancer cells and induce apoptosis.

Product information

CAS Number: 2413716-79-5

Molecular Weight: 860.90

Formula: C43H67Cl2NO12

Chemical Name: (4aS,6aS,6bR,10S,12aR)-10-{[(2R,3R,4R,5S,6R)-3-(2,2-dichloroacetamido)-4,5-dihydroxy-6-({[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid

Smiles: C[C@@]12CC[C@]3(CCC(C)(C)CC3C1=CCC1[C@@]2(C)CCC2[C@]1(C)CC[C@H](O[C@@H]1O[C@H](CO[C@@H]3OC[C@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]1NC(=O)C(Cl)Cl)C2(C)C)C(O)=O

InChiKey: RKZCSSOXYRKYHB-FNBQOOJUSA-N

InChi: InChI=1S/C43H67Cl2NO12/c1-38(2)14-16-43(37(53)54)17-15-41(6)21(22(43)18-38)8-9-26-40(5)12-11-27(39(3,4)25(40)10-13-42(26,41)7)58-35-28(46-34(52)33(44)45)31(50)30(49)24(57-35)20-56-36-32(51)29(48)23(47)19-55-36/h8,22-33,35-36,47-51H,9-20H2,1-7H3,(H,46,52)(H,53,54)/t22?,23-,24+,25?,26?,27-,28+,29-,30+,31+,32+,35-,36-,40-,41+,42+,43-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

AlbA-DCA exhibits the cytotoxicity against the MCF-7 cells, HCT116 cells, A375 cells, 4T1 cells, HBMEC cells and LO2 cells with IC50 values of 0.43 μM, 3.87 μM, 3.78 μM, 1.31 μM, 38.20 μM and 53.14 μM, respectively. AlbA-DCA (2 μM; 24 hours; MCF-7 cells) treatment induces apoptotic cell death in MCF-7 cells. AlbA-DCA (2 μM; MCF-7 cells) treatment could significantly up-regulate the expression of cytochrome c and down-regulate the expression of antiapoptotic protein Bcl-2. AlbA-DCA significantly enhances the expression of caspase-9.

In Vivo:

AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) treatment displays antitumor efficacy and almost completely suppresses tumor progression, and no mouse deaths and no significant changes in body weight are observed. AlbA-DCA has no obvious toxicity of liver and kidney and no major abnormality is observed in heart, liver, spleen, lung, and kidney.

Products are for research use only. Not for human use.